Results From Our Spring 2024 Survey
What we learned, and what’s next: Scientific research can be confusing and overwhelming, and that’s…
Irene Guijarro MunozMay 29, 2024
IASLC Targeted Therapies Recap
#TogetherSeparately: live virtual meetup to summarize data presented on February’s IASLC Targeted Therapies Meeting. March 13 at 3PM…
Irene Guijarro MunozMarch 11, 2024
Looking Ahead: The Future of Diagnostic Testing for Patients
Over the last fifteen years, the introduction of precision medicine has generated renewed hope for…
Irene Guijarro MunozJanuary 7, 2024
2023 RET Cancer Research Update
2023 Happy Lungs Project RET research update On Friday December 8th, the Happy Lungs Project…
Irene Guijarro MunozDecember 18, 2023
Exciting Preclinical Results About Vepafestinib
New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06). Vepafestinib showed selectivity…
Irene Guijarro MunozOctober 10, 2023
Two research studies funded by HLP presented at 2023 ASCO Mtg
Last week was the 2023 American Society of Clinical Oncology (ASCO) conference in Chicago. The…
Irene Guijarro MunozJune 19, 2023
Ellipses Pharma presents ‘encouraging’ data on selective RET inhibitors
Data of the Phase 1 Study of KL590586 (EP0031/A400), presented at ASCO, reported preliminary efficacy…
Irene Guijarro MunozJune 19, 2023
DAVA’s 2nd Hawaii Global Summit on Thoracic Malignancies
The DAVA’s 2nd Hawaii Global Summit on Thoracic Malignancies is a five-day meeting comprising seven…
Irene Guijarro MunozJune 19, 2023
Virtual Event: 2022 RET Cancer Research Update (Watch Video)
The Happy Lungs Project hosted a 2022 Research Update, featuring presentations about advances for RET-positive…
Irene Guijarro MunozDecember 13, 2022
Participants Needed: Epidemiology of Young Lung Cancer Study
Epidemiology of Young Lung Cancer is a clinical study for patients who were diagnosed with…
Irene Guijarro MunozNovember 29, 2022
